NVCR vs. EBS
Compare and contrast key facts about NovoCure Limited (NVCR) and Emergent BioSolutions Inc. (EBS).
Performance
NVCR vs. EBS - Performance Comparison
Loading graphics...
NVCR vs. EBS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVCR NovoCure Limited | -16.16% | -56.61% | 99.60% | -79.65% | -2.30% | -56.61% | 105.34% | 151.70% | 65.74% | 157.32% |
EBS Emergent BioSolutions Inc. | -32.20% | 29.29% | 298.33% | -79.68% | -72.83% | -51.48% | 66.08% | -8.99% | 27.57% | 41.50% |
Fundamentals
NVCR:
$1.21B
EBS:
$475.15M
NVCR:
-$1.22
EBS:
$0.94
NVCR:
1.85
EBS:
0.63
NVCR:
3.55
EBS:
0.91
NVCR:
$655.35M
EBS:
$742.90M
NVCR:
$488.47M
EBS:
$0.00
NVCR:
-$130.60M
EBS:
$271.60M
Returns By Period
In the year-to-date period, NVCR achieves a -16.16% return, which is significantly higher than EBS's -32.20% return. Over the past 10 years, NVCR has outperformed EBS with an annualized return of -2.62%, while EBS has yielded a comparatively lower -13.20% annualized return.
NVCR
- 1D
- -0.55%
- 1M
- -19.82%
- YTD
- -16.16%
- 6M
- -22.46%
- 1Y
- -38.13%
- 3Y*
- -43.51%
- 5Y*
- -39.46%
- 10Y*
- -2.62%
EBS
- 1D
- 0.96%
- 1M
- -6.79%
- YTD
- -32.20%
- 6M
- -8.81%
- 1Y
- 76.79%
- 3Y*
- -6.83%
- 5Y*
- -36.39%
- 10Y*
- -13.20%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVCR vs. EBS — Risk / Return Rank
NVCR
EBS
NVCR vs. EBS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for NovoCure Limited (NVCR) and Emergent BioSolutions Inc. (EBS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NVCR | EBS | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.55 | 0.83 | -1.38 |
Sortino ratioReturn per unit of downside risk | -0.50 | 1.94 | -2.44 |
Omega ratioGain probability vs. loss probability | 0.94 | 1.26 | -0.33 |
Calmar ratioReturn relative to maximum drawdown | -0.81 | 1.69 | -2.50 |
Martin ratioReturn relative to average drawdown | -1.29 | 4.27 | -5.56 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| NVCR | EBS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.55 | 0.83 | -1.38 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.49 | -0.36 | -0.13 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.04 | -0.17 | +0.13 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.07 | -0.02 | -0.05 |
Correlation
The correlation between NVCR and EBS is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
NVCR vs. EBS - Dividend Comparison
Neither NVCR nor EBS has paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
NVCR NovoCure Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EBS Emergent BioSolutions Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.65% |
Drawdowns
NVCR vs. EBS - Drawdown Comparison
The maximum NVCR drawdown since its inception was -95.55%, roughly equal to the maximum EBS drawdown of -98.89%. Use the drawdown chart below to compare losses from any high point for NVCR and EBS.
Loading graphics...
Drawdown Indicators
| NVCR | EBS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.55% | -98.89% | +3.34% |
Max Drawdown (1Y)Largest decline over 1 year | -48.30% | -42.95% | -5.35% |
Max Drawdown (5Y)Largest decline over 5 years | -95.55% | -98.14% | +2.59% |
Max Drawdown (10Y)Largest decline over 10 years | -95.55% | -98.89% | +3.34% |
Current DrawdownCurrent decline from peak | -95.19% | -93.79% | -1.40% |
Average DrawdownAverage peak-to-trough decline | -51.47% | -40.60% | -10.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.35% | 16.95% | +13.40% |
Volatility
NVCR vs. EBS - Volatility Comparison
NovoCure Limited (NVCR) has a higher volatility of 16.85% compared to Emergent BioSolutions Inc. (EBS) at 9.05%. This indicates that NVCR's price experiences larger fluctuations and is considered to be riskier than EBS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| NVCR | EBS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.85% | 9.05% | +7.80% |
Volatility (6M)Calculated over the trailing 6-month period | 51.80% | 61.33% | -9.53% |
Volatility (1Y)Calculated over the trailing 1-year period | 69.42% | 93.41% | -23.99% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 81.31% | 102.08% | -20.77% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 71.60% | 79.69% | -8.09% |
Financials
NVCR vs. EBS - Financials Comparison
This section allows you to compare key financial metrics between NovoCure Limited and Emergent BioSolutions Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities